Participants will take the study drug by mouth each day while doctors regularly check for side effects, collect blood samples, and monitor how the medicine moves through the body. Any serious side effects that limit the amount of drug that can be given (dose‑limiting toxicity) are recorded, and doctors look for signs that the disease is responding using accepted criteria. The study continues until sufficient information on safety and appropriate dosing is gathered.

The purpose of this study is to learn how safe AZD3632 is, how well the body tolerates it, how it moves through the body over time, and whether it might help treat these blood cancers. The study is divided into different modules or parts. The first module tests AZD3632 by itself to find the best dose that is both safe and effective. This module also includes a smaller part that looks at whether eating food affects how the body absorbs the medication. The second module tests AZD3632 when given together with posaconazole to see if this combination is safe and to understand how the two medications interact in the body.

During the study, participants will take the study medication and visit the clinic regularly for check-ups. These visits will include physical examinations, blood tests to check how the body is functioning, heart monitoring tests, and assessments to see how the disease is responding to treatment. The doctors will monitor for any side effects and measure various aspects of how the medication works in the body, including the levels of medication in the blood at different times. For participants with acute leukemia, the doctors will look for signs that the cancer is responding, such as a reduction in cancer cells in the bone marrow and blood. For those with myelodysplastic syndromes, the doctors will check whether blood cell counts improve and whether participants need fewer blood transfusions. The study will also track how long any positive responses last and overall survival.

The purpose of the study is to evaluate the safety and tolerability of Eganelisib, both as a standalone treatment and when combined with Cytarabine, in patients whose disease has returned or has not responded to previous treatments. The study will be conducted in two parts. In the first part, different doses of Eganelisib will be tested to find the most suitable dose for further research. In the second part, the study will look at how well the treatment works in controlling the disease.

Participants in the study will receive either Eganelisib alone or in combination with Cytarabine. The study will monitor the participants’ health and any side effects they may experience. The goal is to determine the best dose of Eganelisib and to gather information on its potential benefits for patients with relapsed or refractory AML and HR-MDS. The study is expected to continue until early 2028, with recruitment starting in 2025.

The purpose of this study is to understand how safe and effective S227928 is for patients with these specific blood cancers, especially those whose disease has returned or has not responded to previous treatments. The study will be conducted in two phases. In the first phase, researchers will focus on finding the safest dose of S227928 and how well patients tolerate it, both on its own and in combination with Venetoclax. In the second phase, the study will evaluate how well the combination of S227928 and Venetoclax works in fighting the cancer.

Participants in the study will receive the treatment and be monitored closely by healthcare professionals. The treatment will be given either as a tablet or through an intravenous infusion, which means it will be delivered directly into the bloodstream. The study aims to gather important information about the treatment’s effects on the body, including any side effects and how the body processes the medication. This information will help determine if S227928 could be a beneficial treatment option for patients with these challenging blood cancers.

The purpose of the study is to evaluate how well Eltanexor works in treating patients with a specific mutation in their leukemia called NPM1-mutated AML. Participants in the study will take Eltanexor orally, meaning they will swallow the tablets. The study will monitor the effects of the medication over a period of time to see how the leukemia responds and to check for any side effects. The study aims to gather information on the response rate of the leukemia to the treatment and to observe any significant side effects that may occur.

Throughout the study, participants will be closely monitored by healthcare professionals to ensure their safety and to collect data on the effectiveness of Eltanexor. The study is designed to provide valuable insights into the potential benefits and risks of using Eltanexor for treating relapsed or refractory NPM1-mutated AML, contributing to the development of new treatment options for this challenging condition.

The main goal of the study is to assess the safety and how well patients tolerate the CD19 CAR-T cells treatment. Participants will receive the treatment and be monitored closely to see how their bodies respond. The study will also involve the use of other medications, such as Cyclophosphamide and Fludarabine, which are given to help prepare the body for the CAR-T cell therapy. These medications are administered through injections or infusions.

Throughout the study, participants will have regular check-ups and tests to monitor their health and the effects of the treatment. The study aims to gather information over several months to understand the long-term effects and benefits of the therapy. This research is important for developing new treatments for patients with AML who have limited options. Participants will be contributing to valuable research that could improve future cancer treatments.

The purpose of the study is to find the best dose of CCTx-001 and to see how safe and effective it is for patients with relapsed or refractory AML. The study will be conducted in two phases. In the first phase, the focus will be on determining the safest dose and understanding any side effects. In the second phase, the study will look at how well the treatment works in controlling the leukemia. Patients will receive the treatment through an intravenous infusion, which means the medication is given directly into a vein.

Throughout the study, participants will be closely monitored for any side effects and to see how their leukemia responds to the treatment. The study aims to gather important information that could lead to new treatment options for people with this challenging form of leukemia. Participants will receive regular check-ups and assessments to track their health and the progress of their treatment.

The purpose of the study is to determine the best dose of Quizartinib for different age groups and to assess how well it works in achieving remission, which means the cancer is no longer detectable. The study will also look at the safety of the treatment and how the body processes the medication. Participants will receive Quizartinib along with chemotherapy for up to two cycles, with the option for additional treatment if needed. After this, Quizartinib may be given alone for up to twelve cycles to see if it helps keep the cancer from returning.

This trial is specifically for patients with a mutation called FLT3-ITD, which is found in some cases of AML. The study will monitor how well the treatment works in reducing cancer cells and how long the remission lasts. It will also track any side effects experienced by participants. The goal is to find a safe and effective treatment option for young patients with this type of leukemia.

The purpose of this research is to test how well ziftomenib works in treating people with AML and to find the most appropriate dose that can be given safely. The study is divided into different parts, with the first part focusing on finding the right dose and checking the safety of the medication. The later parts of the study look at how effective the treatment is for different groups of patients with specific genetic changes in their leukemia cells.

During the study, participants receive ziftomenib and are monitored regularly to check how they respond to the treatment. The researchers will collect blood samples and perform various tests to evaluate how well the medication is working and to check for any side effects. The study will also look at how long the beneficial effects of the treatment last and how it affects patients’ overall survival.